Last reviewed · How we verify

Flecainide or Sotalol or Propafenone

Medtronic Cardiac Rhythm and Heart Failure · Phase 3 active Small molecule

Flecainide or Sotalol or Propafenone is a Antiarrhythmic agents (Class I and Class III) Small molecule drug developed by Medtronic Cardiac Rhythm and Heart Failure. It is currently in Phase 3 development for Atrial fibrillation (maintenance of sinus rhythm or rate control), Paroxysmal supraventricular tachycardia, Ventricular arrhythmias. Also known as: Tambocor, Sotalol, Propafenone.

These antiarrhythmic drugs suppress abnormal heart rhythms by blocking sodium and/or potassium channels in cardiac tissue, slowing electrical conduction and prolonging the refractory period.

These antiarrhythmic drugs suppress abnormal heart rhythms by blocking sodium and/or potassium channels in cardiac tissue, slowing electrical conduction and prolonging the refractory period. Used for Atrial fibrillation (maintenance of sinus rhythm or rate control), Paroxysmal supraventricular tachycardia, Ventricular arrhythmias.

At a glance

Generic nameFlecainide or Sotalol or Propafenone
Also known asTambocor, Sotalol, Propafenone
SponsorMedtronic Cardiac Rhythm and Heart Failure
Drug classAntiarrhythmic agents (Class I and Class III)
TargetCardiac sodium channels (Flecainide, Propafenone); cardiac potassium channels and beta-adrenergic receptors (Sotalol)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Flecainide and Propafenone are Class IC antiarrhythmics that primarily block fast sodium channels, markedly slowing conduction velocity. Sotalol is a Class III antiarrhythmic with beta-blocking properties (Class II) that prolongs the action potential duration by blocking potassium channels. All three reduce the automaticity and conduction velocity of ectopic foci, thereby suppressing arrhythmias.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Flecainide or Sotalol or Propafenone

What is Flecainide or Sotalol or Propafenone?

Flecainide or Sotalol or Propafenone is a Antiarrhythmic agents (Class I and Class III) drug developed by Medtronic Cardiac Rhythm and Heart Failure, indicated for Atrial fibrillation (maintenance of sinus rhythm or rate control), Paroxysmal supraventricular tachycardia, Ventricular arrhythmias.

How does Flecainide or Sotalol or Propafenone work?

These antiarrhythmic drugs suppress abnormal heart rhythms by blocking sodium and/or potassium channels in cardiac tissue, slowing electrical conduction and prolonging the refractory period.

What is Flecainide or Sotalol or Propafenone used for?

Flecainide or Sotalol or Propafenone is indicated for Atrial fibrillation (maintenance of sinus rhythm or rate control), Paroxysmal supraventricular tachycardia, Ventricular arrhythmias, Prevention of arrhythmia recurrence in patients with implantable cardioverter-defibrillators.

Who makes Flecainide or Sotalol or Propafenone?

Flecainide or Sotalol or Propafenone is developed by Medtronic Cardiac Rhythm and Heart Failure (see full Medtronic Cardiac Rhythm and Heart Failure pipeline at /company/medtronic-cardiac-rhythm-and-heart-failure).

Is Flecainide or Sotalol or Propafenone also known as anything else?

Flecainide or Sotalol or Propafenone is also known as Tambocor, Sotalol, Propafenone.

What drug class is Flecainide or Sotalol or Propafenone in?

Flecainide or Sotalol or Propafenone belongs to the Antiarrhythmic agents (Class I and Class III) class. See all Antiarrhythmic agents (Class I and Class III) drugs at /class/antiarrhythmic-agents-class-i-and-class-iii.

What development phase is Flecainide or Sotalol or Propafenone in?

Flecainide or Sotalol or Propafenone is in Phase 3.

What are the side effects of Flecainide or Sotalol or Propafenone?

Common side effects of Flecainide or Sotalol or Propafenone include Dizziness or lightheadedness, Dyspnea or shortness of breath, Fatigue, Proarrhythmic effects (new or worsened arrhythmias), Bradycardia (Sotalol), QT prolongation (Sotalol).

What does Flecainide or Sotalol or Propafenone target?

Flecainide or Sotalol or Propafenone targets Cardiac sodium channels (Flecainide, Propafenone); cardiac potassium channels and beta-adrenergic receptors (Sotalol) and is a Antiarrhythmic agents (Class I and Class III).

Related